Reprogramming the immune system

Immunological Reviews

Volumn 185, Issue , 2002, Pages 227-235

  Waldmann, Herman ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN;

ALLOGENIC BONE MARROW TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CLINICAL MEDICINE; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; INJURY; LABORATORY; MEDICAL INFORMATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK; SURGICAL TECHNIQUE; TIME;

ALLERGY AND IMMUNOLOGY; ANIMALS; GRAFT REJECTION; GRAFT SURVIVAL; HISTORY, 20TH CENTURY; HUMANS; IMMUNE SYSTEM; IMMUNE TOLERANCE; MODELS, IMMUNOLOGICAL;

EID: 0036630507     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-065X.2002.18519.x     Document Type: Review

References (103)

1. Acquired immunological tolerance to foreign cells
2. Cellular sites of immunologic unresponsiveness
3. Immunological tolerance in bone marrow-derived lymphocytes. 3. Tolerance induction in primed B cells by hapten conjugates of unrelated immunogenic or 'nonimmunogenic' carriers
4. In vitro tolerance induction of neonatal murine B cells
5. Continuous cultures of fused cells secreting antibody of predefined specificity
6. Rat x rat hybrid myelomas and a monoclonal anti-Fd portion of mouse IgG
7. Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines
8. Removal of T cells from bone marrow for transplantation: A monoclonal antilymphocyte antibody that fixes human complement
9. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1)
10. Use of allogeneic, homozygous bone marrow cells for induction of specific immunological tolerance in mice treated with anti-lymphocyte serum
11. Antilymphocyte serum, donor bone marrow and tolerance to allografts: The journey is the reward
12. Therapy with monoclonal antibodies. Elimination of T cell subsets in vivo
13. Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection: The depletion of T cell subsets in vitro and in vivo
14. Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance
15. Mixed chimerism and transplant tolerance
16. Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype
17. Interaction of rat monoclonal antibodies with human killer cells
18. Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes
19. Immunoglobulin heavy chain locus of the rat: Striking homology to mouse antibody genes
20. Isolation of low-frequency class-switch variants from rat hybrid myelomas
21. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection
22. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells
23. Activation of mouse complement by monoclonal mouse antibodies
24. A repertoire of monoclonal antibodies with human heavy chains from transgenic mice
25. The immunogenicity of chimeric antibodies
26. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
27. Reshaping human antibodies for therapy
28. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis
29. Campath IH allows low-dose cyclosporine monotherapy in 31 cadaveric renal allograft recipients
30. Tolerance of rat monoclonal antibodies: Implications for serotherapy
31. Induction of immune tolerance by administration of monoclonal antibody to L3T4
32. Induction of tolerance by monoclonal antibody therapy
33. Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4 cells
34. Mechanisms of monoclonal antibody-facilitated tolerance induction: A possible role for the CD4 (L3T4) and CD11a (LFA-1) molecules in self-non-self discrimination
35. CD4 monoclonal antibody pairs for immunosuppression and tolerance induction
36. Treatment of murine lupus with F (ab′) 2 fragments of monoclonal anti-body to L3T4. Suppression of autoimmunity does not depend on T helper cell depletion
37. Induction of tolerance in peripheral T cells with monoclonal antibodies
38. Tolerance induction in the peripheral immune system
39. Induction of classical transplantation tolerance in the adult
40. Classical transplantation tolerance in the adult. The interaction between myeloablation and immunosuppression
41. Bone marrow transplantation induces either clonal deletion or infectious disease tolerance depending on the dose
42. The induction of skin graft tolerance in MHC-mismatched or primed recipients: Primed T cells can be tolerized in the periphery with CD4 and CD8 antibodies
43. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies
44. Tolerance in the mouse to MHC mismatched heart allografts, and to rat heart xenografts, using monoclonal antibodies to CD4 and CD8
45. Mechanisms of induction of tolerance to organ allografts
46. Induction of infectious tolerance to MHC incompatible cardiac allografts in CD4 monoclonal antibody-treated sensitized rat recipients
47. Mechanisms in CD4 antibody-mediated transplantation tolerance. Kinetics of induction, antigen dependency and role of regulatory T cells
48. Linked suppression can operate through indirect recognition
49. 'Infectious' transplantation tolerance
50. T cell regulation in adult transplantation tolerance
51. T cell suppression in transplantation tolerance through linked recognition
52. Tolerance and suppression in a primed immune system
53. Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8
54. + suppressor cells block allotransplant rejection
55. Amplification of natural regulatory immune mechanisms for transplantation tolerance
56. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
57. What is the role of regulatory T cells in transplantation tolerance
58. + regulatory cells?
59. Infectious immunological tolerance
60. Combined anti-CD2 and anti-CD3 receptor monoclonal antibodies reduce donor-specific tolerance in a cardiac transplant model
61. Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1
62. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig
63. Transplantation tolerance induced by CTLA4-Ig
64. Ex vivo coating of islet cell allografts with murine CTLA4/Fc promotes graft tolerance
65. Acceptance of primary skin graft after treatment with anti-intercellular adhesion molecule-1 and anti-leukocyte function-associated antigen-1 monoclonal antibodies in mice
66. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways
67. The CD28/B7 system of T cell costimulation
68. Co-existence of Th1- and Th2- type cytokine profiles in anti-CD2 monoclonal antibody-induced tolerance
69. The in vivo mechanism of action of CTLA-4Ig
70. Blocking the CD28-B7 T cell costimulation pathway induces long term cardiac allograft acceptance in the absence of IL-4
71. Distinct mechanisms for the induction and maintenance of allograft tolerance with CTLA-4 Fc treatment
72. + T cells, interferon-γ, and CTLA4
73. + T cell tolerance and linked suppression
74. Anti-CD154 therapeutic antibodies induce infectious transplantation tolerance
75. Targeting signal 1 through CD45RB synergizes with CD40 ligand blockade and promotes long-term engraftment and tolerance in stringent transplant models
76. + T cells or B cells
77. + T cell subset inhibits antigen specific T cell responses and prevents colitis
78. + T cell subsets in determining transplantation rejection or tolerance
79. Regulatory T cells overexpress a subset of Th2 gene transcripts
80. Regulator T cells. Controllers of immunologic self-tolerance
81. Regulatory T cells in autoimmunity. Anergic T cells actively repress T cell responses via the antigen-presenting cell
82. + immunoregulatory T cells is antigen non-specific
83. + T cell subset that inhibits this autoimmune potential
84. + T cells are important for the balance between protective and pathogenic cell-mediated immunity
85. + T cells induce or protect from chronic intestinal inflammation in C.B-17 scid mice
86. CD4 and CD45RB low-density cells from untreated mice present acute allograft rejection
87. + regulatory T cells prevent graft rejection. CTLA-4- and IL-10-dependent immunoregulation of alloresponses
88. + T cells regulate the expansion of peripheral CD4 T cells through the production of IL-10
89. - subpopulations
90. + T cells that prevent spontaneous autoimmune encephalomyelitis
91. - regulatory cells mediate dominant transplantation tolerance
92. IL-10 is required for regulatory T cells to mediate tolerance to alloantigens in vivo
93. Tolerance, danger, and the extended family
94. + regulatory cells that control intestinal inflammation
95. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4
96. Cytotoxic T lymphocyte antigen-4 (CTLA-4) limits the expansion of encephalitogenic T cells in experimental autoimmune encephalomyelitis (EAE)-resistant BALB/c mice
97. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength
98. Monoclonal antibodies as agents to reinduce tolerance in immunity
99. How do monoclonal antibodies induce tolerance? A role for infectious tolerance?
100. + regulatory T cells through GITR breaks immunological self-tolerance
101. + immunoregulatory T cells, gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor
102. Long-term remission of intractable systemic vasculitis with monoclonal antibody therapy
103. Elimination of the immunogenicity of therapeutic antibodies